1355011-22-1

Basic information

• Product Name: 2-(2,6-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(2,6-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS NO: 1355011-22-1
• Molecular Weight: 254.085
• Mol File: 1355011-22-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 298.8±40.0 °C(Predicted)
• Density: 1.10±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-(2,6-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,6-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1355011-22-1)
• EPA Substance Registry System: 2-(2,6-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1355011-22-1)

Safety Data

• Hazardous Substances Data: 1355011-22-1(Hazardous Substances Data)

Usage

Type of compound

boronic ester

Common use

reagent for Suzuki-Miyaura cross-coupling reactions in organic synthesis

Physical state

colorless liquid

Molecular weight

254.11 g/mol

Known for

high stability and reactivity

Usage

production of various organic compounds in pharmaceutical and agrochemical industries

Potential properties

anti-inflammatory and anti-cancer, making it a candidate for new drug development.

Upstream product

• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 117358-51-7 1,3-difluoro-5-methylbenzene 

Downstream Products

• 1586041-49-7 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluoro-4-methylphenyl)thiazole-4-carboxamide 
• 1586045-59-1 2-(2,6-difluoro-4-methylphenyl)thiazole-4-carboxylic acid 
• 1355011-23-2 methyl 6-(2,6-difluoro-4-methylphenyl)-5-fluoropicolinate 

Relevant articles and documents

Oxazolyl pyrimidinone amide compound or medicinal salt thereof, preparation method and application of oxazolyl pyrimidinone amide compound or medicinal salt thereof

The invention discloses an oxazole pyrimidone amide compound or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The oxazole pyrimidone amide compound has the following structural general formula (I) shown in the description, wherein R1 and R2 are respectively and independently selected from hydrogen and C1-3 alkyl, R3 is selected from C1-3 alkyl groups, R4 and R5 are independently selected from 5-6-membered aryl groups, the aryl groups are phenyl groups or heteroaryl groups containing 1-3 heteroatoms, the heteroatoms are selected from oxygen atoms or nitrogen atoms, and the heteroatoms are located at any position on the heteroaryl groups; the aryl is unsubstituted or at least substituted by one or more halogens or C1-3 alkyl groups, C1-3 polyhalogenated alkyl groups and C1-3 alkoxy groups. The invention also discloses an application of the compound as a TRPA1 antagonist, and the compound is used for preparing medicines for treating or preventing diseases, symptoms and/or obstacles regulated by TRPA1, such as pain and the like.

N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS

The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.